These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18506153)

  • 1. Microsomal triglyceride transfer protein inhibition-friend or foe?
    Joy TR; Hegele RA
    Nat Clin Pract Cardiovasc Med; 2008 Aug; 5(8):506-8. PubMed ID: 18506153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms.
    Chang G; Ruggeri RB; Harwood HJ
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):562-70. PubMed ID: 12197314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia.
    Burnett JR
    IDrugs; 2006 Jul; 9(7):495-9. PubMed ID: 16821163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
    Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

  • 8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension and hyperlipidemia].
    Hansen HS; Larsen ML
    Ugeskr Laeger; 2009 Jun; 171(24):2028-30. PubMed ID: 19523369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia.
    Samaha FF; McKenney J; Bloedon LT; Sasiela WJ; Rader DJ
    Nat Clin Pract Cardiovasc Med; 2008 Aug; 5(8):497-505. PubMed ID: 18506154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Untangling the heavy cardiovascular burden of obesity.
    Lavie CJ; Milani RV; Ventura HO
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5(7):428-9. PubMed ID: 18521107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Microsomal triglyceride transfer protein inhibitor].
    Sugimoto T; Yamashita S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():665-70. PubMed ID: 11347150
    [No Abstract]   [Full Text] [Related]  

  • 16. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS; Gradman AH; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
    Dominiczak M
    Curr Opin Lipidol; 2009 Feb; 20(1):79-81. PubMed ID: 19106712
    [No Abstract]   [Full Text] [Related]  

  • 18. Bibliography. Current world literature. Hyperlipidaemia and cardiovascular disease.
    Curr Opin Lipidol; 2000 Aug; 11(4):403-21. PubMed ID: 10945723
    [No Abstract]   [Full Text] [Related]  

  • 19. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.